Search jobs 02-Feb-2021 Global Hemato Oncology Testing Market Is Expected To Grow At A Rate (CAGR) Of 14.8% In The Forecast Period 2020 To 2027
Fior Markets which is the fastest growing market research company. The report provides a comprehensive scope of the market which includes future supply and demand scenarios, changing market trends, high growth opportunities, and in-depth analysis of the future market prospects. The report features real-time developments in the global Hemato Oncology Testing market encompasses a highly structured and comprehensive outlook of the market. It shows market types and applications that are categorized as ideal market segments. The report covers the competitive data analysis of the emerging and prominent players of the market. Along with this, it provides comprehensive data analysis on the risk factors, challenges, and possible new market avenues.
Share this article
BEDMINSTER, N.J. and SINGAPORE, Jan. 18, 2021 /PRNewswire/
Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company s lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
PRIME is a program launched by EMA to optimize development plans and speed up evaluation of medicines that demonstrate major therapeutic advantage over existing treatments, or otherwise benefit patients without treatment options. Through this program, EMA offers enhanced support to medicine developers including early interaction and dialogue, and a pathway for accelerated evaluation by the agency.
Share this article
LAS VEGAS, Jan. 12, 2021 /PRNewswire/ DelveInsight s
Diffuse Large B-cell Lymphoma Market Research Report report delivers thorough comprehension of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology along with the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The DLBCL market report provides analysis of current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
Diffuse Large B-cell Lymphoma Market Report s Few Key Highlights
CAR-T therapies and the pipeline agents,
Lisocabtagene maraleucel, are expected to contribute significantly to revenues because of the premium pricing and clinical benefits in Relapsed-Refractory (R/R) patients.
BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data Lund, Sweden - January 11, 2021- BioInvent International AB today. | January 16, 2021
BioInvent streamlines agreement on anti-FcyRllB antibody, BI-1206, ahead of Phase I/II data
LUND, Sweden, Jan. 11, 2021 /PRNewswire/ BioInvent International AB ( BioInvent or the Company ) (OMXS: BINV) today announces it has restructured a clinical development agreement with Cancer Research UK (CRUK), the world s leading cancer charity, for its unique anti-FcyRIIB antibody, BI-1206. In exchange for a one-time payment, the revised deal simplifies and reduces BioInvent s obligations to CRUK, which provides BioInvent with more flexibility to carry out development and partnering activities with BI-1206. It follows BioInvent s exclusive licensing agreement with CASI Pharmaceuticals for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong and Macau.